In a world where about a third of the adult male in the global population smokes, it’s tough not to take notice of its negative impact on the society as a whole. According to the WHO, if the smoking trends do not ease up, one in every 6 adults will die of smoking-related illness (e.g. emphysema and lung cancer) by 2030. Currently, smoking-related diseases kill 1 in 10 adults worldwide.
Chilling reports aside, the threat of diseases caused by smoking has not gone unnoticed by the public. In the recent years, pharmaceutical companies have helped smokers quit the habit by coming up with smoking cessation aids; from nicotine patches to nicotine gums. However, some smokers have smoked too much for far too long that the damage done to their respiratory systems are already irreversible.
At the American Association for Cancer Research (AACR) Annual Meeting this year, iloprost took to the stage with positive results of its Phase II trial testing its effect on cancer cells in the lungs of former smokers. The study, headed by Dr. Robert L. Keith of the University of Colorado, tested the antihypertensive drug, iloprost 150 mcg, on former and current smokers, who have had at least a 20 pack year (1 pack/20 cigarettes per day for 20 years) in their lifetime. After taking biopsies of former smokers’ lungs, the study reported significant reductions in lesions. However, the biopsies of current smokers showed no changes.
Iloprost CAS# 78919-13-8 is a prostaglandin analog of the naturally occurring PG12, a prostaglandin with antimetastatic properties. In patients with lung cancer, PG12 levels are reduced in the lungs. However, in healthy patients, PG12 levels are increased.
The study is an entirely new treatment concept in the battle against lung cancer. However, the drug still has a long way to go before it can even make it to the phase 3 of clinical testing. This is why LGM Pharma provides continuous supply support to institutions currently involved in its research and development. The company understands the critical role of a reliable supply chain for these institutions, which is why they never compromise on the timely delivery of their products.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.